8-epi-prostaglandin F2 alpha (8-epi-PGF2 alpha) and related compounds are novel prostanoid produced by a noncyclooxygenase mechanism involving lipid peroxidation. Renal ischemia-reperfusion injury increased urinary excretion of these compounds by 300% over baseline level. Intrarenal arterial infusion at 0.5, 1, and 2 micrograms/kg per min induced dose-dependent reductions in glomerular filtration rate (GFR) and renal plasma flow, with renal function ceasing at the highest dose. Micropuncture measurements (0.5 microgram/kg per min) revealed a predominant increase in afferent resistance, resulting in a decrease in transcapillary hydraulic pressure difference, and leading to reductions in single nephron GFR and plasma flow. These changes were completely abolished or reversed by a TxA2 receptor antagonist, SQ 29,548. Competitive radioligand binding studies demonstrated that 8-epi-PGF2 alpha is a potent competitor for [3H]SQ 29,548 binding to rat renal arterial smooth muscle cells (RASM) in culture. Furthermore, addition of 8-epi-PGF2 alpha to RASM or isolated glomeruli was not associated with stimulation of arachidonate cyclooxygenase products. Therefore, 8-epi-PGF2 alpha is a potent preglomerular vasoconstrictor acting principally through TxA2 receptor activation. These findings may explain, in part, the beneficial effects of antioxidant therapy and TxA2 antagonism observed in numerous models of renal injury induced by lipid peroxidation.
Introduction
The generation and pathophysiologic relevance of reactive oxygen metabolites during glomerular injury is well established (1) . We have reported the discovery of a series of novel prostaglandin F2 (PGF2)-like compounds produced by a noncyclooxygenase mechanism involving free radical catalyzed lipid peroxidation (2) . These compounds are easily detected in normal human plasma and urine, and their production is markedly enhanced in animal models with free radical-induced injury (2) . Further, we examined the actions of one of these compounds, 8-epi-prostaglandin F2, , in normal rat kidney, and demonstrated extremely potent and selective renal vasoconstrictive effects in the low nanomolar concentration range (2) . The fact that these prostanoids are present in urine and their formation increases in situations involving free radical-induced injury, combined with the potent renal constrictor action demonstrated for 8-epi-PGFu,, suggests a potential role for this family of eicosanoids as novel mediators of the renal functional deterioration that accompanies free radical-induced glomerular injury (1, 2) .
In the present study, using micropuncture techniques, we examined the precise responses of glomerular hemodynamics to intrarenal arterial administration of 8-epi-PGF2, in vivo in the normal rat. In addition, we assessed the role of thromboxane receptors in mediating its renal effects both in vivo and in vitro. Furthermore, to investigate the pathophysiologic relevance of these compounds, we assessed their urinary excretion rate in ischemic acute tubular necrosis, an oxygen free radicalmediated experimental model of renal injury (3, 4) . Methods 8-epi-PGF2, (gift from Dr. Gordon Bundy, The Upjohn Co., Kalamazoo, MI). Aliquots of 8-epi-PGF2. were dissolved in ethanol and were stored at -70°C. Immediately before use, they were diluted with 0.1 N PBS to the required concentration. Eicosanoid purity and concentration in stock solutions and in syringes used for intrarenal injections were verified periodically by gas chromatography/negative ion mass spectrometry as previously described (5) .
Physiological measurements. Clearance studies were performed on anesthetized adult male Munich-Wistar rats weighing 200-230 g prepared according to the protocols described previously (6) . In brief, after Inactin anesthesia (Andrew Lockwood & Associates, Sturtevant, WI), the left femoral artery catheter was used to sample blood and to monitor mean systemic arterial pressure (MAP)' by means of a pressure transducer (model P23Db, Statham Instrument; Oxnard, CA) connected to a direct writing recorder (Gould Inc. Instruments Div., Cleveland, OH). After a tracheostomy, PE-50 catheters were inserted into both jugular veins for infusions of plasma, inulin, and paraaminohip-1. Abbreviations used in this paper: FF, filtration fraction; GFR, glomerular filtration rate; Hct, hematocrit; Kf, glomerular capillary ultrafiltration coefficient; MAP, systemic arterial pressure; PAH, paraaminohippuric acid; PE, efferent arteriolar pressure; PGC, glomerular capillary pressure; PT, proximal tubular pressure; RA, afferent arteriolar resistance; RASM, renal arterial vascular smooth muscle cells; RBF, renal blood flow; RPF, renal plasma flow; RE, efferent arteriolar resistance; SNGFR, single nephron glomerular filtration rate; SNFF, single nephron filtration fraction; SNPF, single nephron glomerular plasma; V, urine flow rate. puric acid (PAH) (7.5% and 1.6% solution, respectively, in 0.9% NaCl at 1.2 ml/h), and other experimental solutions. The left kidney was exposed by a left subcostal incision, separated from the surrounding fat, and suspended on a Lucite holder. The kidney surface was bathed with warm isotonic NaCi. A 30-gauge needle was placed in the abdominal aorta at the takeoff ofthe left renal artery, through which a maintenance infusion of 0.9% NaCI was initiated at a rate of 0.025 ml/min. Homologous rat plasma was administered intravenously at a rate of 10 ml/kg per h for 45 min, followed by a reduction in an infusion rate to 1.5 ml/kg per h for the remainder of the experiment. Previously, this protocol has been shown to adequately replace surgically induced plasma losses, thus maintaining euvolemia (7) . In all experiments, measurements were started 60 min after the onset of plasma infusion and carried out as follows: one to three samples of urine from the experimental kidney were collected, each over 10 min, for the determination of urine flow rate (V), inulin and PAH concentrations, and for the calculation of whole kidney glomerular filtration rate (GFR) and renal plasma flow (RPF). For these urine collections, indwelling ureteral catheters (PE 10) were used. Coincident with these urine collections, two or three samples of femoral arterial blood were obtained in each period for determination of hematocrit (Hct) and plasma concentration ofinulin and PAH. Whole kidney inulin and PAH clearances were performed during baseline conditions and repeated during administration of 8-epi-PGF2, and other experimental conditions to be described.
Inulin concentrations in plasma and urine were determined by the macroanthrone method (8) . PAH concentrations in urine and plasma were determined according to the method of Smith et al. (9) .
Experiments were performed on four groups of rats as follows. Group I: time control (n = 7). In this group, baseline measurements were performed and repeated during a 30-min infusion of vehicle (0.1 N PBS).
Group II: intrarenal arterial 8-epi-PGF2, dose response (n = 21). In this group, whole kidney measurements were performed during baseline conditions and during the infusion of8-epi-PGF2, in the following doses: Group IIA: 0.5 Ag/kg/min (n = 7); group IIB: 1 ug/kg/min (n = 7); group IIC: 2 Asg/kg/min (n = 7). In our previous study (2) , we demonstrated that the plasma concentration of 8-epi-PGF2, 30 min after the initiation of a 5-ytg/kg per min intravenous infusion was 34 nM (-I ng/ml). This concentration is equivalent to that which is observed in free-radical related injuries in rats (CC14-induced liver injury and diquat treatment in selenium deficiency). In our current study, we chose the doses described above, which theoretically deliver similar intrarenal concentrations of 8-epi-PGF2,,.
Since the experimental period in group II was associated with a time-dependent severe and progressive reduction in renal perfusion, measurements were performed in one 15-min period. Group IV(n = 7): micropuncture measurements during8-epi-PGF2.
infusion. In this group, glomerular micropuncture measurements were performed during baseline conditions and repeated during 8-epi-PGF2, administration at 0.5 ug/kg per min.
All micropuncture experiments were performed on anesthetized adult male Munich-Wistar rats that weighed 200-225 g and were prepared for micropuncture according to the protocols described previously (12) . The preparation is identical to that described above for whole kidney clearance studies, except that 3H-inulin (300 gCi/experimental period in 0.9% NaCl at 1.2 ml per h) from New England Nuclear (Boston, MA) was used instead of nonradiolabeled inulin. Micropuncture measurements were started 60 min after the onset of plasma infusion and carried out as follows: 2-min samples of fluid were collected from surface proximal convolutions to determine the flow rate and inulin concentration. Concomitantly, femoral arterial blood samples were obtained during each period to determine Hct and plasma protein and inulin concentrations. Three samples of blood were obtained from surface efferent arterioles (star vessels) to determine efferent arteriolar protein concentration. Time-averaged hydraulic pressures were measured in surface glomerular capillaries (Poc), proximal tubules (PT), and surface efferent arterioles (PE) using a servo-null micropipette transducer system (model 5; Instrumentation for Physiology & Medicine, Inc., San Diego, CA) and micropipettes with outer tip diameters of 2-3 ,um containing 2 M NaCl. Colloid osmotic pressures of plasma entering and leaving glomerular capillaries, single nephron glomerular filtration rate (SNGFR), single nephron filtration fraction (SNFF), glomerular capillary ultrafiltration coefficient (Kf), resistances of single afferent (RA) and efferent (RE) arterioles, and single nephron glomerular capillary plasma flow (SNPF) were determined using equations described in detail elsewhere (13) . The concentrations ofinulin in tubular fluid and plasma were determined by measuring the radioactivity of 3H-inulin in a scintillation counter (Beckman Instruments, Inc., Fullerton, CA). Protein concentrations in efferent arteriolar and femoral arterial blood plasmas were determined using a fluorometric method developed by Viets et al. (14) .
Group V (n = 4): ischemic acute tubular necrosis model. In this group, urine was collected from the catheter in the left ureter for 15 min under baseline conditions and the left renal artery was clamped for 30 min. 20 min after relief of the clamp from the renal artery, urine was again collected for 15 min. PGF2<,-compounds in these samples was analyzed after thin layer chromatography purification by gas chromatography/negative ion mass spectrometry as described in (5) , and the urinary excretion rate of PGF2,-compounds was expressed in pg/min.
Eicosanoids production by 8-epi-PGF2, from isolated glomeruli and rat renal arterial vascular smooth muscle cells (RASM). Glomeruli were isolated from rat kidneys as described previously (15) . RASM were cultured from medial explants of rat main renal arteries by the modified method of Ross (16 I. Examination of renal responses to this compound at the single-nephron level in group IV (Fig. 2 ) revealed that the decreases in whole kidney GFR and RPF were accompanied by parallel reductions in SNGFR and SNPF, the former falling from 47.1±2.2 to 34.8±2.5 nl/min (P < 0.0005), and the latter fell from 204.3±12.6 to 146.3±11.7 nl/min (P < 0.0005). The change in FF was not significant (from 0.25±0.01 to 0.24±0.01 (NS). Accompanying these reductions in SNGFR and SNPF were simultaneous 8-epi-PGF2<,-induced augmentations of both RA and RE, which increased from 1.09±0.11 to 1.79±0. 19 10'°dyn * scm5 (P < 0.0005), and from 0.80±0.09 to 1.11±0.11 10'°dyn * s * cm-5 (P < 0.0005), respectively. The proportionately greater increase in RA led to a significant reduction in PGC, which decreased from 45.3±0.4 to 40.1±0.7 mmHg (P < 0.0005). PT also fell slightly during 8-epi-PGF2,a administration, from 13±1 to 111 ± mmHg (P < 0.05). Mean net transcapillary hydraulic pressure difference (AP) was reduced significantly from 33.6±0.8 to 27.7±0.5 mmHg (P < 0.005). The presence of filtration pressure disequilibrium during 8-epi-PGF2, administration allowed for the calculation of unique values for Kf in all the experimental animals. The administration of 8-epi-PGF2o, was not associated with a significant change in the mean value for this parameter, which changed from 0.064±0.0 10 to 0.064±0.009 nl/(s. mmHg) (NS).
When 8-epi-PGF2a was administered in the presence of a specific TxA2 receptor antagonist, SQ 29,548, a marked modification of the former's renal actions was noted. In the presence ofSQ 29,548, 8-epi-PGF2< administration was without a significant effect on either Hct or MAP. Hct changed from 46.5±0.8 to 46.3±0.7 vol% (NS), and MAP changed from 103±4 to 105±4 mmHg (NS). In contrast to the effect of 8-epi-PGF2, infusion alone (group IIC), however, 8-epi-PGF2, administration (2 jig/kg per min) in the presence of SQ 29,548 was not associated with any significant changes in GFR and RPF. GFR changed from 0.92±0.05 to 0.89±0.04 ml/min (1.8±5.9% fall), and RPF changed from 4.85±0.14 to 5.07±0.22 ml/min (3.2±3.9% increase (Fig. 3) fore (C) and after (E) the adminis- (116±4 vs. 113±4 mmHg in control period, P < 0.025) was also reduced to baseline level (111±4 mmHg, NS vs. baseline value). Additionally, the presence of a cyclooxygenase inhibitor, ibuprofen (2 mg/kg i.v.), had no effect on the renal responses to 8-epi-PGF2a (2 ,g/kg per min) observed in group IIC animals described above (data not shown).
In group V animals, the urinary excretion rates of PGF2, compounds increased from 21.6±1.4 under basal condition to 68.2±47.6 pg/min (P < 0.05) during the reperfusion period (Fig. 5) .
In vitro studies Secondary release of eicosanoids by 8-epi-PGF2a. The calculated cross-reactivity to 8-epi-PGF2, of the antibody for TxB2 was 0.5%. The results obtained from the experiments were 10 min * ĩ . . . . corrected based on this cross-reactivity. The cross-reactivities of the antibodies for PGE2 and 6-keto-PGFa, were negligible.
As shown in Fig. 6 , incubation of isolated glomeruli with increasing amounts of8-epi-PGF2,, was not associated with significant changes in the amount ofTxB2 (Fig. 6 A) and PGE2 (Fig. 6  B) in the supernatant. No significant change was again noted in the value for 6-keto-PGFIa, ( (Fig. 7 B) . This result, coupled with the failure of 8-epi-PGF2, to stimulate secondary release of arachidonate cyclooxygenase products from isolated glomeruli and RASM (Fig. 6) , strongly supports the in vivo observations, suggesting that direct interaction of 8-epi-PGF2, with TxA2 receptors is the principal mechanism underlying its renal constrictor actions.
The formation of these prostanoids catalyzed by free radicals (2), coupled with the potent renal vascular activity demonstrated for 8-epi-PGF2, at pathologically relevant doses in the present study, suggests a potential pathophysiological role for those compounds as novel mediators in oxidant-related renal injury. In fact, our data demonstrated that during the reperfusion period of ischemic acute tubular necrosis, an oxygen free radical-mediated experimental model ofrenal injury (3, 4) , urinary excretion rate ofthese eicosanoids increased by more than 300%.
In summary, we examined the responses of the glomerular microcirculation in the rat to 8-epi-PGF2a, a novel noncyclooxygenase-derived prostanoid produced as a result of free radical catalyzed lipid peroxidation. Our experiments demonstrate that the primary sites of action of 8-epi-PGF2, are in preglomerular and possibly mesangial smooth muscle, where it exerts potent constrictor effects. These actions result in reductions in renal perfusion and probably in glomerular capillary surface area, thereby depressing GFR. We have also sown that in rat renal circulation, the constrictor effects of 8-epi-PGF2, are caused by its activation of thromboxane receptors. These observations, coupled with the increased production of these prostanoids in certain oxygen free radical-related experimental models, suggest a pathophysiological role for free radical-generated prostaglandins in mediating the renal functional derangements observed in oxidant-related renal injury. In addition, our findings might provide an explanation for the salutary effects of TxA2 antagonism demonstrated in models of lipid peroxidation-induced renal pathophysiology (25) .
